SI-BONE, Inc.
SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991_q226earningsrel.htm EX-99.1 Document Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Q
Si-Bone, Inc. (SIBN) is scheduled to report Q2 2026 earnings on Aug. 3 after market close, with results expected at 4:09 PM ET. The consensus outlook cited for the quarter includes revenue of $55.34 million and EPS of -$0.15 (USD).
SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. sibn-20260604 0001459839 false 0001459839 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 8-K __________________________________________________________
Over the past 7 days, alphai's AI scored 1 news story mentioning SIBN (SI-BONE, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SIBN coverage spans financial news, earnings and insider activity.
In the last 30 days, SIBN insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($369K). The most active reporter was DUNN JEFFREY W with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Guidance raise plus profitability improvement suggests improving demand and operating leverage, with near-term focus on Q3/Q4 product and reimbursement catalysts.
Earnings preview sets expectations for the Aug 03 print; the key trade is positioning around whether results beat or miss the provided consensus.
Near-term lease extension reduces uncertainty on office occupancy costs but is unlikely to materially change operating outlook.
Insider selling can modestly pressure sentiment, but this is not a 10b5-1 plan and is relatively small versus typical liquidity.
Insider selling is a modest negative signal, but this specific sale was not tied to a 10b5-1 plan per the filing details.
alphai scores every news story that mentions SIBN with an AI model for sentiment and relevance, and aggregates insider trades from SI-BONE, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991_q226earningsrel.htm EX-99.1 Document Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Q
6 min readSi-Bone, Inc. (SIBN) is scheduled to report Q2 2026 earnings on Aug. 3 after market close, with results expected at 4:09 PM ET. The consensus outlook cited for the quarter includes revenue of $55.34 million and EPS of -$0.15 (USD).
1 min readSI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. sibn-20260604 0001459839 false 0001459839 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ FORM 8-K __________________________________________________________
2 min readDavis Timothy E JR sold 3,500 shares of SI-BONE, Inc. (SIBN) at $14.14 on 2026-05-29.
2 min readDavis Timothy E JR sold 3,780 shares of SI-BONE, Inc. (SIBN) at $14.47 on 2026-05-28.
1 min readSI-BONE (Nasdaq: SIBN) announced it will participate in the BofA Securities 2026 Healthcare Conference in Las Vegas, NV, on Tuesday, May 12, 2026. Management will host a fireside chat at 8:00 a.m. PT / 11:00 a.m. ET, with live audio available via webcast on the company’s investor relations page. The webcast will also be archived for at least 90 days for replay.
2 min readImpax Asset Management Group plc increased its stake in SiBone (NASDAQ:SIBN) by 17.1% in the fourth quarter, bringing their total holdings to $23.66 million. Other institutional investors have also adjusted their positions in SiBone, with 98.11% of the stock owned by institutional investors and hedge funds. Despite some insider selling, analysts maintain a "Moderate Buy" consensus rating for SiBone, with an average target price of $24.00.
3 min readAmerican Century Companies Inc. increased its stake in SiBone (NASDAQ:SIBN) by 22.5%, acquiring an additional 521,683 shares and now holding a total of 2,838,107 shares valued at $41.8 million. SiBone reported a smaller-than-expected quarterly loss of $0.04 per share, beating estimates by $0.09, and generated revenues of $56.35 million. Analysts currently have a "Moderate Buy" rating for SiBone with a consensus target price of $24.67.
3 min readSi-Bone (SIBN) reported strong Q4 2025 financial results, with EPS of -$0.04 significantly beating the -$0.12 forecast and revenue reaching $56.3 million, exceeding expectations of $54.7 million. The company achieved a 15% revenue growth year-over-year, positive cash flow, and positive adjusted EBITDA for the first time, leading to a modest 0.97% increase in stock price. Looking ahead, Si-Bone projects continued revenue growth by FY2026 and plans to expand product offerings and market penetration, especially with new products like INTRA Ti and strategic partnerships.
4 min readSANTA CLARA, Calif., Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. ( NASDAQ:SIBN ) , a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler 37th Annual Healthcare Conference in New York, NY. ...
3 min read
